During the third quarter, Gladstone Institutional Advisory LLC opened a new position in Madrigal Pharmaceuticals by acquiring 1,093 shares at a total cost of approximately $501,000, as disclosed in its latest 13F filing with the SEC. This move follows significant adjustments by other large investors in the prior quarter: Adage Capital Partners GP L.L.C. boosted its holding by 96.3% to 376,163 shares, representing a position valued in excess of $113.8 million; Norges Bank initiated a stake valued at roughly $53.4 million; Invesco Ltd. expanded its holding by 50.7% to 200,356 shares, worth about $60.6 million; BNP Paribas Financial Markets increased its position nearly twentyfold to 69,037 shares, worth $20.9 million; and Artisan Partners Limited Partnership raised its stake by 46.3% to 201,571 shares, representing $61.0 million. Collectively, institutional investors now control 98.5% of Madrigal’s outstanding shares.

In its latest quarterly report, Madrigal Pharmaceuticals posted a loss of $5.08 per share, missing the consensus estimate by $3.07 and driving a negative net margin of 39.0%. The company ended the period with a debt-to-equity ratio of 0.54, a quick ratio of 3.26 and a current ratio of 3.44, reflecting a strong liquidity profile. Analysts project a full-year EPS of -23.47, underscoring continued investment in clinical development. Madrigal’s market capitalization stands at approximately $11.7 billion, its price-to-earnings-growth ratio is 3.94, and the stock sports a beta of -1.00, suggesting limited correlation with broader market movements.

Insiders have reduced their exposure by selling a total of 77,056 shares over the past three months, representing 21.5% of insider-owned stock. Notable dispositions include the sale of 1,958 shares by a board member and 4,173 shares by the chief financial officer, each transaction triggering double-digit percentage reductions in individual ownership. On the research front, one firm maintains a Strong Buy rating, twelve rate the stock as Buy, two as Hold and one as Sell, yielding an overall consensus of Moderate Buy. Price objectives among analysts range substantially, with the midpoint indicating potential upside of more than 15% from current levels.